Get notified when MYGN files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Goodwill Impairment (worsened) — A new $4.5 million goodwill impairment was recorded in 2026, reducing the Women's Health reporting unit's goodwill to zero, following a much larger $234.7 million impairment in 2025.
NASDAQ: MYGN MYRIAD GENETICS INC 10-Q

Myriad Genetics to sell Prenatal Health unit to Labcorp for $210M; Q3 revenue slips 1.5% to $202.7M

Filed November 6, 2026 · Period ending September 30, 2026 · Compared to 10-Q Nov 4, 2025 · ~1 min read

Key Changes

  • high

    Agreed to sell Prenatal Health business to Laboratory Corporation of America for $210 million cash plus inventory value, subject to regulatory approvals.

    Subsequent Events verify on EDGAR →
  • high

    Goodwill impairment of $4.5 million in Q1 2026 reduced Women's Health reporting unit goodwill to zero; total goodwill now $47.1 million.

    Notes: Goodwill verify on EDGAR →
  • high

    Recognized a $10.3 million reduction to revenue for tests delivered in prior periods during the nine months ended September 30, 2026.

    Notes: Revenue view on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (OWL 10-Q) is open in full — no account needed.

Partner

Trade MYGN commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov View full financials on EDGAR ↗

Figures/quotes linked to EDGAR · Narrative written by AI · Nov 9, 2026 · How we verify